AirSculpt Technologies (AIRS)
Provides private-pay body-contouring procedures through AirSculpt centers in the U.S. and Canada.
Something off on this page? Send us feedback.
Sells direct medical procedure services through AirSculpt centers, with revenue from upfront private-pay fat removal, fat transfer, skin tightening, and cellulite treatments. Its footprint is concentrated in the U.S. with a Canadian presence, and the model depends on surgeon-owned professional associations and demand for minimally invasive aesthetics.
Runs one reportable segment: direct medical procedure services delivered through AirSculpt centers. The core AirSculpt procedure removes fat and tightens skin; adjacent offerings include fat-transfer procedures, Power BBL, Up a Cup, Hip Flip, AirSculpt+, and AirSculpt Smooth.
Operates a North American center network concentrated in the U.S., with Canada included after exiting an unprofitable London center. Centers are designed around private-pay procedures paid upfront, avoiding reimbursement exposure.
Execution rests on a branded, minimally invasive method, surgeon relationships, office-based accreditation, and a premium patient experience. Clinical work is structured through surgeon-owned Professional Associations because many states restrict the corporate practice of medicine; patent protection for the AirSculpt method is limited to the United States.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior target | Target |
|---|---|---|---|---|
| May 14, 2026 | Leerink Partners | Target | $6 | $4.50 |
| Nov 11, 2025 | Leerink Partners | Target | $5 | $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $18.8M · Total debt $70.5M · Total assets $193.3M · Shareholders' equity $104.8M
- Revenue
- $42.9M
- Operating income
- $294.0K
- Net income
- −$1.1M
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 25, 2022 | Aug 26 | Sep 14 | $0.41 | special dividend |
| Institutions97 holders · as of Mar 31, 2026 | 57.02% | 41.11M shares | |
| Insiders12 holders · as of Jun 1, 2026 | 42.25% | 30.46M shares | |
| Strategic holders1 holder · as of Aug 8, 2025 | 16.31% | 11.76M shares | |
| Adds to | 115.58% |
72.10M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 115.58%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vesey Street Capital Partners, L.L.C.Institution | 42.06% | 30.32M | 13Fas of Mar 31, 2026 |
Aaron RollinsInsiderdirector, 10 percent owner, officer: Executive Chairman | 20.42% | 14.72M | 13Gfiled Jun 1, 2026 ↗ |
EBS Aggregator Blocker Holdings, LLCStrategic | 16.31% | 11.76M | 13Gfiled Aug 8, 2025 ↗ |
Jorey Chernett1Insider10 percent owner | 10.38% | 6.78M | 13Gfiled Apr 20, 2026 ↗ |
Parian Ultreia LPInstitution | 9.35% | 6.74M | 13Gfiled Apr 21, 2026 ↗ |
| See all 25 → | |||
- Jorey Chernett's transaction reports restate only vehicles that traded; the 2026 ownership statement (6.78M) plus the 700.2K net shares acquired since is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 17, 2026 | Jorey Chernett | 10 percent owner | +40,000 | $2.54 |
| Apr 14, 2026 | Jorey Chernett | 10 percent owner | +20,000 | $2.60 |
| Apr 7, 2026 | Jorey Chernett | 10 percent owner | +60,000 | $2.93 |
| Apr 3, 2026 | Jorey Chernett | 10 percent owner | +90,000 | $2.82 |
| Mar 23, 2026 | Jorey Chernett | 10 percent owner | −6,547 | $2.00 |
- InMode
RF aesthetics platforms for body contouring and skin tightening
- AbbVie
Allergan Aesthetics portfolio led by CoolSculpting
- Apyx® Medical
Surgical aesthetics devices for fat removal and tissue contraction
- Bausch Health
Solta Medical devices for liposuction, skin tightening, and lasers
- S.B.C. Medical Group
Public clinic MSO spanning aesthetic healthcare and dermatology
- Establishment Labs
Breast-aesthetics platforms competing with fat-transfer options
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AirSculpt Technologies | $2.47 | +1.65% | $173.5M | — | — | 1.2 | −2.5% |
| InMode | $14.93 | −0.67% | $859.3M | 12.2 | 11.3 | 2.3 | −0.2% |
| AbbVie | $261.51 | −0.08% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Apyx® Medical | $3.07 | −0.23% | $129.7M | — | — | 2.2 | +22.1% |
| Bausch Health | $6.82 | −0.07% | $2.55B | — | 1.5 | 0.2 | +11.2% |
| S.B.C. Medical Group | $4.21 | +0.72% | $435.0M | 9.0 | 8.7 | 2.5 | +13.4% |
| Establishment Labs | $75.30 | +0.44% | $2.20B | — | — | 9.0 | +31.7% |
| Median | 12.2 | 10.0 | 2.4 | +12.3% |